These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15906354)

  • 21. Screening of TP53 mutations by DHPLC and sequencing in brain tumours from patients with an occupational exposure to pesticides or organic solvents.
    Loyant V; Jaffré A; Breton J; Baldi I; Vital A; Chapon F; Dutoit S; Lecluse Y; Loiseau H; Lebailly P; Gauduchon P
    Mutagenesis; 2005 Sep; 20(5):365-73. PubMed ID: 16105905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bladder cancer risk and personal hair dye use.
    Andrew AS; Schned AR; Heaney JA; Karagas MR
    Int J Cancer; 2004 Apr; 109(4):581-6. PubMed ID: 14991581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis.
    Remy E; Rebouissou S; Chaouiya C; Zinovyev A; Radvanyi F; Calzone L
    Cancer Res; 2015 Oct; 75(19):4042-52. PubMed ID: 26238783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors in clonal development from superficial to invasive bladder cancer.
    Landman J; Droller MJ
    Cancer Surv; 1998; 31():5-15. PubMed ID: 15281314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis.
    Traczyk-Borszynska M; Borkowska E; Jablonowski Z; Jedrzejczyk A; Pietrusinski M; Kaluzewski B; Sosnowski M; Borowiec M
    Neoplasma; 2016; 63(6):952-960. PubMed ID: 27596295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
    George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
    J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 alterations in bladder tumors from arsenic and tobacco exposed patients.
    Moore LE; Smith AH; Eng C; DeVries S; Kalman D; Bhargava V; Chew K; Ferreccio C; Rey OA; Hopenhayn C; Biggs ML; Bates MN; Waldman FM
    Carcinogenesis; 2003 Nov; 24(11):1785-91. PubMed ID: 12919957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined analysis of smoking, TP53, and FGFR3 mutations in Tunisian patients with invasive and superficial high-grade bladder tumors.
    Ouerhani S; Rouissi K; Kourda N; Marrakchi R; Bougatef K; Riadh Ben Slama M; Sfaxi M; Chebil M; Ben Jilani S; Benammar Elgaaied A
    Cancer Invest; 2009 Dec; 27(10):998-1007. PubMed ID: 19909015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer.
    Kelsey KT; Hirao T; Schned A; Hirao S; Devi-Ashok T; Nelson HH; Andrew A; Karagas MR
    Br J Cancer; 2004 Apr; 90(8):1572-6. PubMed ID: 15083187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study.
    Dalbagni G; Ren ZP; Herr H; Cordon-Cardo C; Reuter V
    Clin Cancer Res; 2001 Sep; 7(9):2797-801. PubMed ID: 11555595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occupation and cancer - follow-up of 15 million people in five Nordic countries.
    Pukkala E; Martinsen JI; Lynge E; Gunnarsdottir HK; Sparén P; Tryggvadottir L; Weiderpass E; Kjaerheim K
    Acta Oncol; 2009; 48(5):646-790. PubMed ID: 19925375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
    Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
    Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.
    Le Calvez F; Mukeria A; Hunt JD; Kelm O; Hung RJ; Tanière P; Brennan P; Boffetta P; Zaridze DG; Hainaut P
    Cancer Res; 2005 Jun; 65(12):5076-83. PubMed ID: 15958551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
    Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer.
    Hazra A; Grossman HB; Zhu Y; Luo S; Spitz MR; Wu X
    Genes Chromosomes Cancer; 2004 Dec; 41(4):330-8. PubMed ID: 15390186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
    Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
    J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.